Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3409457 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Benzene SCHEMBL9751882 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL30307036 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL597672 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL2509 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL125188 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL30671620 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL30812783 | 1.00 | TSHR (1.00) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| SCHEMBL9871011 | 0.97 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6HTR6 | |
| Hydrochloric Acid SCHEMBL11436653 | 0.97 | TSHR (0.94) | TSHRSMN1; SMN2POLBCYP2D6HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720073-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2025111563-A1 | MILK PEPTIDE COMPOSITIONS FOR PHARMACEUTICAL AND COSMECEUTICAL USE | MATRUBIALS INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4504736-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | Nuvalent, Inc. (US) | 2025-02-12 | — | — | EP | claimed |
| WO-2024245364-A1 | SOLID FORMS OF A MACROCYCLIC FARNESYLTRANSFERASE INHIBITOR AND FORMULATIONS THEREOF, AND METHODS OF PREPARING AND USING THE MACROCYCLIC COMPOUND AND ITS SOLID FORMS | KURA ONCOLOGY, INC. (US) | 2024-12-05 | — | — | WO | claimed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | claimed |
| WO-2023196900-A9 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| CN-117887464-A | SiGe/Si and SiO 2 Is a selective etching solution | 湖北兴福电子材料股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2023196900-A1 | SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS | NUVALENT, INC. (US) | 2023-10-12 | — | — | WO | claimed |
| CN-107851760-A | Improved, coated or treated microporous battery separators, rechargeable lithium batteries, systems, and related methods of manufacture and/or use | 赛尔格有限责任公司 | 2018-03-27 | — | — | CN | claimed |
| CN-103917221-B | Comprise the surface treating composition of shielding salt | 宝洁公司 | 2016-08-24 | — | — | CN | claimed |
| US-20260027128-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | PAION UK LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| US-12527870-B2 | Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| US-20260007652-A1 | Selective Modulators of AhR-Regulated Transcription and Method for Using Such Modulators to Treat Cancer | OREGON STATE UNIVERSITY (US) | 2026-01-08 | — | — | US | disclosed |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | GILEAD SCIENCES, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12486270-B2 | Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-12-02 | — | — | US | disclosed |
| CN-101035790-A | (1S,5S) -3- (5, 6-dichloropyridin-3-yl) -3, 6-diazabicyclo [3.2.0] heptane benzenesulfonate | ABBOTT LAB (US) | 2007-09-12 | — | — | CN | disclosed |
| WO-2007038524-A2 | COCRYSTALLIZATION METHODS | SSCI, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| US-5891499-A | USING MIXTURE OF SODIUM SULFATE, CARBOXYMETHYL CELLULOSE ANDPROPYLENE GLYCOL | BALSANO CHIMICA IND (IT) | 1999-04-06 | — | — | US | disclosed |
| CN-1198771-A | Acidic cleaning compositions | PROCTER & GAMBLE (US) | 1998-11-11 | — | — | CN | disclosed |
| US-4299912-A | Process for the production of printing plates | FUJI PHOTO FILM CO., LTD. (JP) | 1981-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527870-B2 | Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof | JAK1, JAK3, PTMS | TSHR 1155/4885SMN1; SMN2 4711/4885POLB 2615/4885 |
| US-12486270-B2 | Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder | EPHA1, EPHB2, EPHB1 | TSHR 548/4885SMN1; SMN2 2715/4885POLB 4564/4885 |
| US-20260007652-A1 | Selective Modulators of AhR-Regulated Transcription and Method for Using Such Modulators to Treat Cancer | AHR, YAP1, ARNT | TSHR 1028/4885SMN1; SMN2 2197/4885POLB 3449/4885 |
| US-12492189-B2 | Solid forms of an HIV capsid inhibitor | ZC3HAV1, GTF3C3, ZC3HAV1L | TSHR 4139/4885SMN1; SMN2 959/4885POLB 3024/4885 |
| US-20260027128-A1 | ORALLY INHALED AND NASAL BENZODIAZEPINES | GABRA2, GABRP, GABRE | TSHR 227/4885SMN1; SMN2 1169/4885POLB 2775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.